Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Chief Financial Officer | February 23, 2026 | February 24, 2026 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Director | June 16, 2026 | June 18, 2026 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | EVP & CFO | November 03, 2017 | November 08, 2017 |
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | CHIEF FINANCIAL OFFICER | February 08, 2024 | February 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Foghorn Therapeutics Inc.
Report date February 23, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2036-02-22 | Direct | 400,000 |
Reported balance
After 2026-02-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-23 · Grant · Acquired 400,000 · Balance 400,000 F1: The option vests as to 25% of the underlying shares of common stock on February 23, 2027, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until the option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the underlying shares of common stock on February 23, 2027, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until the option is fully vested.
IOVANCE BIOTHERAPEUTICS, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 90,316 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 90,316 · Balance 90,316 F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.
RIGEL PHARMACEUTICALS INC
Report date November 03, 2017 · Filed November 08, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-11-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-11-03 · Exercise / conversion · Acquired 100,000 · Balance 100,000 Row 2 · 2017-11-03 · Sale · Disposed 100,000 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2017. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2025-01-26 | Direct | 75,000 |
Reported balance
After 2017-11-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-03 · Exercise / conversion · Disposed 100,000 · Balance 75,000 F2: The option vested monthly over two years from January 1, 2015. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2017.
F2: The option vested monthly over two years from January 1, 2015.
Tvardi Therapeutics, Inc.
Report date February 08, 2024 · Filed February 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,012 |
Reported balance
After 2023-02-08 transaction · row 1
1 source rowRow 1 · 2023-02-08 · Sale · Disposed 5,488 · Balance 8,012 F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 14, 2023 accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 14, 2023 accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 21:15 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 90,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075856 · tm2618145-2_4seq1.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,316 Underlying: Common Stock · 90,316 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:02 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 400,000 | $5.75 Strike: $5.75 | $2,300,000.00 |
DisclosureSEC source: 0001363984-26-000004 · primarydocument.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2036-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on February 23, 2027, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until the option is fully vested. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:08 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 67,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-060253 · tm2518181-4_4seq1.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,546 Underlying: Common Stock · 67,546 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0001104659-24-119195 · tm2428483-1_4seq1.xml · derivative · entry 3 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options became exercisable in four equal quarterly installments of 12,500 each following the date of grant, which was February 16, 2015. F5 · balance_after: Such aggregate number reflects the remainder of such stock options granted on February 16, 2015, but does not include any other stock options held by such Reporting Person. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | SaleCommon Stock | 50,000 | $10.06 | $503,000.00 |
DisclosureSEC source: 0001104659-24-119195 · tm2428483-1_4seq1.xml · nonDerivative · entry 2 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 F2 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F3 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $10.05 and $10.105. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 50,000 | $7.45 | $372,500.00 |
DisclosureSEC source: 0001104659-24-119195 · tm2428483-1_4seq1.xml · nonDerivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 49,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-071370 · tm2417165-2_4seq1.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,303 Underlying: Common Stock · 49,303 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:55 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031112 · tm248017d8_4seq1.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:32 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002528 · form4-02052024_090254.xml · nonDerivative · entry 1 Maynard Ryan D · CIK 0001363984 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:21 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 51,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-069507 · tm2318216-4_4seq1.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,955 Underlying: Common Stock · 51,955 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:38 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 81,000 | $0.00 Strike: $10.06 | $0.00 |
DisclosureSEC source: 0001209191-23-015571 · doc4.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 1, 2023, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 08, 2023 Filed Feb 12, 2024 22:15 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,488 | $0.53 | $2,908.64 |
DisclosureSEC source: 0001415889-24-003404 · form4-02122024_100201.xml · nonDerivative · entry 1 Maynard Ryan D · CIK 0001363984 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,012 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on September 14, 2023 accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 20:42 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0001209191-22-049931 · doc4.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-09-12 F1 · derivative.exercise_date: 25% of the shares will vest and become exercisable on September 12, 2023 and the remainder will vest over the following 36 equal monthly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 21:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantDeferred Restricted Stock Unit · Derivative | 51,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071054 · tm2218366-5_4seq1.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,204 Underlying: Common Stock · 51,204 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2 · derivative.exercise_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. F2 · derivative.expiration_date: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. Read SEC document |
| May 31, 2022 Filed Jun 3, 2022 00:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | PurchaseCommon Stock | 7,500 | $6.75 | $50,587.50 |
DisclosureSEC source: 0001104659-22-067762 · tm2217576d4_4seq1.xml · nonDerivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 20:18 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $26.33 | $0.00 |
DisclosureSEC source: 0001104659-21-088251 · tm2121236-3_4seq1.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-06-29 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant, such that the options will be fully vested and exercisable on June 29, 2022. Read SEC document |
| June 08, 2020 Filed Jun 11, 2020 00:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $32.17 | $0.00 |
DisclosureSEC source: 0001104659-20-072138 · tm2022303d2_4.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-07 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant, such that the options will be fully vested and exercisable on June 8, 2021. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 21:16 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $19.93 | $0.00 |
DisclosureSEC source: 0001144204-19-030595 · tv523380_4.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-06-09 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service, unless the Reporting Person is terminated for cause, in which case the options shall terminate immediately. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 21:07 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $14.45 | $0.00 |
DisclosureSEC source: 0001250853-18-000100 · primary_doc.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2028-07-16 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service, unless the Reporting Person is terminated for cause, in which case the options shall terminate immediately. Read SEC document |
| November 03, 2017 Filed Nov 8, 2017 02:07 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001179110-17-013850 · edgar.xml · derivative · entry 3 Maynard Ryan D · CIK 0001363984 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 100,000 shares Expires 2025-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested monthly over two years from January 1, 2015. Read SEC document |
| November 03, 2017 Filed Nov 8, 2017 02:07 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 100,000 | $3.90 | $390,000.00 |
DisclosureSEC source: 0001179110-17-013850 · edgar.xml · nonDerivative · entry 2 Maynard Ryan D · CIK 0001363984 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2017. Read SEC document |
| November 03, 2017 Filed Nov 8, 2017 02:07 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 100,000 | $2.14 | $214,000.00 |
DisclosureSEC source: 0001179110-17-013850 · edgar.xml · nonDerivative · entry 1 Maynard Ryan D · CIK 0001363984 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 21:34 UTC | IOVANCE BIOTHERAPEUTICS, INC. LBIO · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001250853-17-000051 · primary_doc.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service unless the Reporting Person is terminated for cause, in which case the options are terminated. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-17-006153 · edgar.xml · derivative · entry 2 Maynard Ryan D · CIK 0001363984 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-01-26 F2 · derivative.exercise_date: On January 26, 2016 the reporting person was granted an option to purchase 150,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. On April 19, 2017, the Compensation Committee determined that the performance conditions had been achieved, resulting in full vesting of the option. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001179110-17-006153 · edgar.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2024-02-27 F1 · derivative.exercise_date: On February 27, 2014 the reporting person was granted an option to purchase 125,000 shares of common stock. The option vested based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. As previously reported on April 4, 2016, the Compensation Committee determined that the performance condition had been achieved with respect to 62,500 shares of common stock. On April 19, 2017, the Compensation Committee determined that the performance conditions had been achieved with respect to the remaining 62,500 shares of common stock, resulting in full vesting of the option. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 00:24 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001179110-17-001817 · edgar.xml · derivative · entry 1 Maynard Ryan D · CIK 0001363984 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: The shares vest monthly over four (4) years from January 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.